In addition, the PI3/AKT kinase mammalian target of the rapamycin (mTOR) pathway is altered in HNSCC tumors, and agents targeting it are in clinical development to be used in combination treatment with chemotherapy [45]. The gene discussed is MTOR; the disease is head and neck squamous cell carcinoma.